Chemed Reports Mixed 2025 Results: EPS Decline Amid Revenue Growth, Major Share Buyback, and New Cyber Lawsuits
CHE is trading near its 52-week low of $385 (2.9% above the low).
Summary
Chemed's 2025 annual report shows revenue growth but a decline in EPS. Key events include a favorable resolution of a $50.3M Medicare audit, a $428M share repurchase, a significant increase in Medicare cap adjustments, and new class action lawsuits following a cybersecurity breach.
Key Events · Earnings and Guidance · CHE
-
2025 Financial Performance
Consolidated service revenues increased 4.1% to $2.53 billion, but net income decreased 12.2% to $265.2 million, and diluted EPS fell to $18.34 from $19.89 in 2024.
-
Favorable Medicare Audit Resolution
VITAS successfully resolved a $50.3 million Medicare overpayment demand, with an Administrative Law Judge ruling largely in its favor and most deposited funds being refunded in April 2025.
-
Significant Share Repurchase Program
The company repurchased $428.035 million worth of capital stock (932,500 shares) in 2025, with $127.3 million remaining authorized under the February 2011 program.
-
Increased Medicare Cap Adjustment
VITAS recorded a $27.161 million Medicare cap revenue reduction in 2025, a substantial increase from $8.414 million in 2024, impacting revenue for several programs.
Analysis · CHE · Industrial Applications And Services
Chemed Corporation's 2025 annual report reveals a mixed financial performance, with consolidated service revenues increasing by 4.1% to $2.53 billion, primarily driven by its VITAS segment. However, net income decreased by 12.2% to $265.2 million, and diluted EPS fell to $18.34 from $19.89 in 2024. A significant positive development is the favorable resolution of a $50.3 million Medicare overpayment demand against VITAS, with an Administrative Law Judge ruling largely in the company's favor and most deposited funds being refunded. The company also executed a substantial share repurchase program in 2025, buying back $428 million worth of stock. Counteracting these positives, VITAS recorded a significantly higher Medicare cap adjustment of $27.2 million in 2025, up from $8.4 million in 2024, indicating increased repayment liabilities for some programs. Furthermore, the company disclosed a cybersecurity incident in October 2025 involving a PHI breach, leading to multiple class action lawsuits, though management believes cyber insurance will cover costs above a $500,000 deductible. Despite the EPS decline and new legal risks, the strong liquidity position with no outstanding debt and $404.5 million in unused credit facilities provides financial flexibility.
At the time of this filing, CHE was trading at $396.05 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $5.6B. The 52-week trading range was $385.00 to $623.61. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.